Comparative Pharmacology
Head-to-head clinical analysis: FML S versus KOVANAZE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FML S versus KOVANAZE.
FML-S vs KOVANAZE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorometholone is a synthetic corticosteroid that binds to the glucocorticoid receptor, modulating gene expression to inhibit phospholipase A2 activity, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production. This results in decreased inflammation, edema, and immune cell infiltration. Sulfacetamide is a sulfonamide antibiotic that competitively inhibits dihydropteroate synthase, blocking folate synthesis and bacterial growth.
KOVANAZE (norepinephrine and phenylephrine) is a combination of two vasopressors: norepinephrine, an α1-adrenergic receptor agonist with β1-adrenergic activity, and phenylephrine, a selective α1-adrenergic receptor agonist. Both agents cause vasoconstriction and increase blood pressure via activation of α1-adrenergic receptors on vascular smooth muscle.
1-2 drops of 0.1% ophthalmic suspension into the conjunctival sac every 4 hours; may increase to every 2 hours in severe inflammation.
Intravenous bolus of 1 mg/kg over 10 minutes, followed by intravenous infusion of 0.02 mg/kg/min for 4 hours, then 0.01 mg/kg/min for 20 hours.
None Documented
None Documented
2.8-3.5 hours; prolonged to 8-12 hours in renal impairment or in neonates
Terminal elimination half-life: approximately 7-9 hours following nasal administration; clinical significance: supports twice-daily dosing regimen
Renal (65-75% as unchanged drug and metabolites), biliary/fecal (15-25%)
Renal excretion of unchanged drug: ~20-30%; fecal/biliary elimination: minimal (<5%); remainder as metabolites
Category C
Category C
Ophthalmic Antibiotic/Corticosteroid Combination
Antihistamine + Corticosteroid Combination